Company Overview: Bioline RX Ltd.

Industry News

25 May

BioLineRx Reports First Quarter 2017 Financial Results

TEL AVIV, Israel, May 25, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the first quarter ended March 31, 2017. Highlights and achievements during the first quarter 2017 and to date: Continued advancing the Company’s lead...

Read more

16 May

BioLineRx to Report First Quarter 2017 Results on May 25, 2017

TEL AVIV, Israel, May 16, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its unaudited financial results for the quarter ended March 31, 2017 on Thursday, May 25, 2017, before the US markets open. The Company will...

Read more

3 May

BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA

TEL AVIV, Israel, May 3, 2017 /PRNewswire/ — – Initiation of Phase 3 registrational study expected in second half of this year – Study to focus on stem cell mobilization for autologous transplantation in multiple myeloma patients BioLineRx Ltd. (NASDAQ/TASE: BLRX, BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and...

Read more

31 Mar

BioLineRx Prices $25 Million Underwritten Public Offering

TEL AVIV, Israel, March 31, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical stage biopharmaceutical development company focused on oncology and immunology, today announced that it has priced an underwritten public offering of approximately 29.4 million American Depositary Shares (“ADSs”), each representing one (1) of its ordinary shares,...

Read more

27 Mar

BioLineRx’s AGI-134 to be Presented at AACR 2017

Tel Aviv, Israel – March 27, 2017 – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that AGI-134,  an immunotherapy for the treatment of multiple cancers, obtained through its recently announced acquisition of Agalimmune Ltd., will be featured at the upcoming American...

Read more

23 Mar

BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-Oncology Pipeline

TEL AVIV, Israel, March 23, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it has acquired Agalimmune Ltd., a private UK-based company with an innovative, anti-cancer immunotherapy platform. Acquisition consideration consisted of a $6 million upfront payment, of...

Read more

23 Mar

BioLineRx Reports Year End 2016 Financial Results

TEL AVIV, Israel, March 23, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX,  TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the year ended December 31, 2016. Highlights and achievements in 2016 and to date: Acquired Agalimmune Ltd., a UK-based biopharmaceutical company...

Read more

16 Mar

BioLineRx to Report Annual 2016 Results on March 23, 2017

TEL AVIV, Israel, March 16, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its audited annual financial results for the year ended December 31, 2016 on Thursday, March 23, 2017, before the US markets open. The Company will...

Read more

Page 1 of 812345...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address